Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inos 41
- Development stage
- Unknown
- Lead developer
- Bion Therapeutics
- Administration
- Oral
01
Overview
Inos 41 is an oral combination nutraceutical developed and marketed by Bion Therapeutics, specifically formulated to support women's health and manage the symptoms of polycystic ovary syndrome (PCOS). The formulation contains a synergistic blend of myo-inositol, D-chiro inositol, chromium, vitamin D3, and L-methylfolate. These active ingredients work together to improve insulin sensitivity, restore hormonal balance, promote regular menstrual cycles, and enhance overall ovarian function. Inos 41 is commercially available as an oral tablet.
- Brand names
- Inos 41Inos41Inos-41
- Other names
- Inos 41 TabletInos41 TabletInos-41 Tablet
02
Targets
VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Inos 41.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inos 41.